Each ml of the solution for injection contains 20 mg meloxicam and 150 mg ethanol (as preservative).

Metacam 20 mg/ml solution is a non-steroidal anti-inflammatory drug (NSAID) for use in cattle, pigs and horses.
Cattle
For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.
For use in diarrhoea, in combination with oral rehydration therapy, to reduce clinical signs in calves of over one week of age and young non-lactating cattle.
For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.
Pigs
For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.
For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.
Horses
For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.
For the relief of pain associated with equine colic

Cattle: Single subcutaneous or intravenous injection at a dose rate of 0.5mg meloxicam/kg bodyweight (i.e. 2.5 ml/100 kg bodyweight) in combination with antibiotic therapy or with oral rehydration therapy as appropriate.
Pigs: Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg bodyweight (i.e. 2.0ml/100kg bodyweight) in combination with antibiotic therapy, as appropriate. If required, a second administration of meloxicam can be given after 24 hours.
Horses: Single intravenous injection at a dosage of 0.6 meloxicam/kg bodyweight (i.e. 3.0ml/100kg bodyweight). Metacam 15mg/ml oral suspension may be used for the continuation of treatment at a dosage of 0.6 mg meloxicam/kg bodyweight, 24 hours after administration of the injection.

Do not use in horses less than 6 weeks of age.
Do not use in pregnant or lactating mares.
Do not use in horses producing milk for human consumption.
Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastro-intestinal lesions. Do not use in case of hypersensitivity to the active substance or to any of the excipients.
For the treatment of diarrhoea, do not use in animals less than one week of age.
Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.
Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.
In case of inadequate relief of pain when used in the treatment of equine colic, careful re-evaluation of the diagnosis should be made as this could indicate the need for surgical intervention,
Subcutaneous, intramuscular as well as intravenous administration is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in less than 10% of the cattle treated in clinical studies.
In horses, a transient swelling at the injection site can occur but resolves without intervention. In very rare cases anaphylactoid reactions may occur and should be treated symptomatically.
In case of overdosage, symptomatic treatment should be initiated.
If side effects occur, treatment should be discontinued and the advice of a veterinarian should be sought
Operator warnings
Accidental self-injection may give rise to pain. People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.
In case of accidental self-injection, seek medical advice immediately and show the package insert or label to the physician.
Disposal Advice
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
For animal treatment only.
Keep out of reach of children.
Withdrawal Period
Cattle:
Meat and offal – 15 days.
Milk – 5 days.
Pigs:
Meat and offal – 5 days.
Horses:
Meat and offal - 5 days.

Shelf life of broached vial: 28 days
Do not use after the expiry date stated on the carton and on the bottle.
Avoid introduction of contamination during use.

POM-V

Colourless glass injection vials of 50 ml, sealed with a rubber stopper and aluminium cap.

Pharmacodynamic properties
Meloxicam is a non-steroidal anti inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic properties. Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B2 induced by E. coli endotoxin administration in calves, lactating cows and pigs.
Pharmacokinetic properties
Absorption
After a single subcutaneous dose of 0.5mg meloxicam/kg, Cmax values of 2.1μg/ml and 2.7μg/ml were reached after 7.7 hours and 4 hours in young cattle and lactating cows, respectively. After two intramuscular doses of 0.4mg meloxicam/kg, a Cmax value of 1.9 μg/ml was reached after 1 hour in pigs.
Distribution
More than 98% of meloxicam is bound to plasma proteins. The highest meloxicam concentrations are to be found in liver and kidney. Comparatively low concentrations are detectable in skeletal muscle and fat.
Metabolism
Meloxicam is predominately found in plasma. In cattle, meloxicam is also a major excretion product in milk and bile where as urine contains only traces of the parent compound. In pigs, bile and urine contain only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive. The metabolism in horses has not been investigated.
Elimination
Meloxicam is eliminated with a half life of 26 hours and 17.5 hours after subcutaneous injection in young cattle and lactating cows, respectively. In pigs, after intramuscular injection, the mean plasma elimination half life is approximately 2.5 hours. In horses, after intravenous injection meloxicam is eliminated with a terminal half-life of 8.5 hours. Approximately 50% of the administered dose is eliminated via urine and the remainder via faeces.